Alzheimer’s is a disease that eats up brain cells and destroys vital mental functions, and the main symptoms include confusion and memory loss. With time it causes dementia, a condition that limits a person’s independence and social skills. Even though the illness can’t be cured, getting good treatment can be of great help.
For years, researchers have tried to find an effective treatment for Alzheimer’s disease to no avail. However, new research now indicates that the answer lies in psychedelics. The only challenge is that psychedelic substances are criminalized in many countries, including the U.S.
There have been groundbreaking findings concerning the medicinal value of psychedelics, thanks to work at research centers that focus on it. One of these is the John Hopkins University Center for Psychedelic & Consciousness research. They are behind the rediscovery of the therapeutic benefits of psilocybin. Case studies of PTSD patients at the research center revealed how it helped improve their overall well-being and provided some mental stability.
After learning of the potential health benefits of psychedelic “magic” mushrooms, a researcher Shlomi Raz founded a science company Eleusis, focused on exploring psychedelics. Through his research, he uncovered the powerful nature of psilocybin, especially in dealing with psychiatric disorders. Psilocybin is the main component in magic mushrooms and which the researcher is investigating to establish its medicinal value.
His study reveals that this psychedelic substance could have anti-inflammatory properties necessary for treating Alzheimer’s disease. The research is therefore aimed at identifying how doses of LSD can help slow down the progression of the disease during its early stages. If successful, this could be a potential game-changing therapeutic way of treating patients, unlike conventional methods.
Alzheimer’s disease is caused by a build-up of a protein fragment known as the amyloid plaque that spreads in the brain and destroys its cells.
Raz came to this conclusion after specifically targeting the causative agents in the brain. By slowing down the accumulation of the toxins in the brain, you’ll attain positive results, and prevent further destruction. He revealed that psychedelics not only improve mental health but also inhibit toxins. LSD is effective because it impacts the serotonin 2A receptor for longer periods.
These findings could be helpful especially since previous drugs have suffered clinical failures. One is left to wonder why pharmaceuticals haven’t picked up on this. The fact that psychedelics are hindered from making it to the market is the main challenge.
Even though Alzheimer’s disease is complex, and other factors limit its scientific growth, Raz’s findings are worth taking up. It provides a new challenge on how to deal with the disease safely without causing hallucinogenic effects. He promises to continue with clinical trials which he can then publish in Psychopharmacology journals.
His research shows that psychedelics can also treat other mental illnesses such as anxiety and depression. A finding also backed by John Hopkins medical research studies. They’ve proven that LSD if administered in the right doses, has mild physiological effects, hence safe to use.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.